Online inquiry

IVTScrip™ mRNA-Anti-alpha toxin&
lukE, ASN-1(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3282MR)

This product GTTS-WQ3282MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets alpha toxin&
lukE gene. The antibody can be applied in Staphylococcal infections research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq WP_000473596.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2828033; 59700577
UniProt ID P09616; A0A0H2WWN3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-alpha toxin&
lukE, ASN-1(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3282MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2830MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG-403
GTTS-WQ12734MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ1225MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABR-217620
GTTS-WQ11109MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MDX-060
GTTS-WQ2056MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AH-PD1
GTTS-WQ10652MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY-3819253
GTTS-WQ4948MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ2083MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AIN457
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW